

**PR-0009-F3**

**VER. 03.02**

**Effective Date: 07/16/2014**

Page 1 of 5

BPV Case

ID: \_\_\_\_\_

Affix BPV Case ID Label

Form Completed By: \_\_\_\_\_

Date on Which Form Was Completed:

\_\_\_\_/\_\_\_\_/\_\_\_\_  
(MM/DD/YYYY)

Tissue Bank ID: \_\_\_\_\_

### Lung Slide Pathology Review

1. Slide ID examined by pathologist:
  
2. Parent specimen ID of the sample from which this slide was derived:
  
3. Organ of origin:  
Select One:
  - ☐ Lung
  - ☐ Other (specify)  
If Other was selected, specify other organ of origin:

PR-0009-F3

VER. 03.02

Effective Date: 07/16/2014

Page 2 of 5

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Completed: \_\_\_\_/\_\_\_\_/\_\_\_\_  
 (MM/DD/YYYY)

**4. Histologic type:**

Select All That Apply:

- ☐ Adenocarcinoma of lung, acinar (WHO code: 8550/3)
- ☐ Adenocarcinoma of lung, bronchioalveolar (WHO code: 8250/2)
- ☐ Adenocarcinoma of lung, bronchioalveolar, mixed nonmucinous and mucinous or indeterminate (WHO code: 8254/3)
- ☐ Adenocarcinoma of lung, bronchioalveolar, mucinous (WHO code: 8253/3)
- ☐ Adenocarcinoma, of lung, bronchioalveolar, nonmucinous (WHO code: 8252/3)
- ☐ Adenocarcinoma of lung, clear cell (WHO code: 8210/3)
- ☐ Adenocarcinoma of lung, fetal
- ☐ Adenocarcinoma of lung, mixed subtype (specify) (WHO code: 8333/3)

**Specify types and %:**

- ☐ Adenocarcinoma of lung, mucinous (colloidal) (WHO code: 8480/3)
- ☐ Adenocarcinoma of lung, mucinous cystadenocarcinoma (WHO code: 8470/3)
- ☐ Adenocarcinoma of lung, papillary (WHO code: 8260/3)
- ☐ Adenocarcinoma of lung, signet ring (WHO code: 8490/3)
- ☐ Adenocarcinoma of lung, solid with mucin production (WHO code: 8230/3)
- ☐ Squamous cell carcinoma (WHO code: 8070/3)
- ☐ Papillary variant of squamous cell carcinoma (WHO code: 8052/3)
- ☐ Clear cell variant of squamous cell carcinoma (WHO code: 8084/3)
- ☐ Small cell variant of squamous cell carcinoma (WHO code: 8073/3)
- ☐ Basaloid variant of squamous cell carcinoma (WHO code: 8083/3)
- ☐ Other (specify)

**If Other was selected, record other histologic type:**

5. Greatest tumor dimension on slide: \_\_\_\_\_ (mm)

6. Percent of cross-sectional surface area of entire slide composed of tumor focus (includes necrotic tumor): \_\_\_\_\_%

7. Percent of tumor nuclei by cell count of the entire slide (number of tumor epithelial cell nuclei as compared to all cell nuclei): \_\_\_\_\_%

8. Percent of cross-sectional surface area of entire slide composed of necrotic tissue: \_\_\_\_\_%

**Note:** BPV case acceptance criteria require necrosis percentage of <20% of the entire slide AND tumor content of ≥50% tumor nuclei.

**PR-0009-F3**
**VER. 03.02**
**Effective Date: 07/16/2014**

Page 3 of 5

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

 Date Completed: \_\_\_\_/\_\_\_\_/\_\_\_\_  
 (MM/DD/YYYY)

**Histologic Profile Quantitative Assessment of Tumor Should Total 100%**
**9. Histologic profile quantitative assessment:**

Percent viable tumor by surface area (not including stroma): \_\_\_\_\_%

Percent necrotic tumor by surface area: \_\_\_\_\_%

Percent tumor stroma by surface area: \_\_\_\_\_%

Percent non-cellular component by surface area: \_\_\_\_\_%

(i.e., mucin, hemorrhage, blood clot, etc.)

**If present, describe non-cellular component:**

Histologic profile total % (should equal 100%): \_\_\_\_\_%

**10. Histologic grade (AJCC 7th edition):**

Select One:

- ☐ G1: Well differentiated
- ☐ G2: Moderately differentiated
- ☐ G3: Poorly differentiated
- ☐ G4: Undifferentiated
- ☐ GX: Cannot be assessed

**Tumor Staging per AJCC 7th Edition**
**11. pT: Pathologic spread primary tumor (AJCC 7th edition):**

Select One:

- ☐ pTX
- ☐ pT0
- ☐ pTis
- ☐ pT1
  - ☐ pT1a
  - ☐ pT1b
- ☐ pT2
  - ☐ pT2a
  - ☐ pT2b
- ☐ pT3
- ☐ pT4

**PR-0009-F3**
**VER. 03.02**
**Effective Date: 07/16/2014**

Page 4 of 5

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

 Date Completed: \_\_\_\_/\_\_\_\_/\_\_\_\_  
 (MM/DD/YYYY)

**12. pN: Pathologic spread lymph nodes (AJCC 7th edition):**

Select One:

- ☐ pNX
- ☐ pN0
- ☐ pN1
- ☐ pN2
- ☐ pN3

**13. M: Distant metastases (AJCC 7th edition):**

Select One:

- ☐ cM0
- ☐ cM1
  - ☐ cM1a
  - ☐ cM1b
- ☐ pM1
  - ☐ pM1a
  - ☐ pM1b

**14. Pathologic tumor stage group (AJCC 7th edition):**

Select One:

- ☐ Occult carcinoma
- ☐ Stage 0
- ☐ Stage IA
- ☐ Stage IB
- ☐ Stage IIA
- ☐ Stage IIB
- ☐ Stage IIIA
- ☐ Stage IIIB
- ☐ Stage IV

**15. Did pathology review of the hematoxylin and eosin slide derived from quality control formalin-fixed paraffin-embedded tumor tissue confirm the histological type to be eligible for BPV study?**

Select One:

- ☐ Yes
- ☐ No

**PR-0009-F3**

**VER. 03.02**

**Effective Date: 07/16/2014**

Page 5 of 5

BPV Case ID: \_\_\_\_\_

Tissue Bank ID: \_\_\_\_\_

Form Completed By: \_\_\_\_\_

Date Completed: \_\_\_\_/\_\_\_\_/\_\_\_\_  
(MM/DD/YYYY)

**16. This slide meets the microscopic analysis criteria of the BPV project of necrosis percentage of <20% AND tumor content of ≥50% tumor nuclei:**

Select One:

- ☐ Yes  
☐ No

**If No is selected, specify what findings do not meet the microscopic analysis criteria of the BPV project:**

**17. Pathology review comments:**

#### **Concordance With Diagnostic Pathology Report**

**18. This slide is consistent with the findings of the diagnostic pathology report for this case:**

Select One:

- ☐ Yes  
☐ No

**If No is selected, specify what findings are not consistent with the diagnostic pathology report:**

**19. Name of local biospecimen source site reviewing pathologist:**

**20. Date of slide review by the pathologist:**

**21. Data entry in the local pathology review form was performed by:**